<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hupperts, Raymond</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PR—Fampridine Improves Mobility in Patients with MS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-17</style></pages><abstract><style  face="normal" font="default" size="100%">Prolonged release (PR)-fampridine treatment resulted in sustained and clinically meaningful improvement in walking ability and balance throughout a 6-month treatment period in individuals with multiple sclerosis (MS). The Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis study [MOBILE; NCT01597297; Hupperts R et al. ACTRIMS/ECTRIMS 2014 (poster P922)] evaluated the effect of PR-fampridine on walking ability, dynamic and static balance, and subjective impressions of well-being.</style></abstract><number><style face="normal" font="default" size="100%">29</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>